Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02798120 · ClinicalTrials.gov registry record · Phase 3

P3 Long Term Safety Study of Once Daily SB204 in Acne

A Phase 3 study of Acne Vulgaris, sponsored by Novan.

Completed
Registry status
Phase 3
Development phase
601
Enrollment target
20
Study locations

NCT02798120: Completed Phase 3 study of Acne Vulgaris, sponsored by Novan.

NCT02798120 is a Phase 3 study of Acne Vulgaris that has completed, run by Novan. The registered enrollment target is 601 participants, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02798120, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Novan.

COMPLETED
Registry status
Phase 3
Development phase
601 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.

Primary Outcome

This outcome measure shows the number of subjects with at least one ongoing adverse event from the pivotal studies (NI-AC301 and NI-AC302) at the time they rolled over into this study (NI-AC303). The final study visit (Week 12) for the pivotal studies served as the Baseline visit for this study. Subjects who were assigned to SB204 in the pivotal studies are denoted as SB204 Experienced and subjects who were assigned to Vehicle Gel on the pivotal studies are denoted as SB204 Naive.

Conditions Studied

Interventions

  • DRUG SB204 4%

Study Locations (20)

California

  • CIL #146 - Anaheim
  • CIL #139 - Cerritos
  • CIL #216 - Chula Vista
  • CIL #186 - Fresno
  • CIL #210 - Fresno
  • CIL #174 - Huntington Beach
  • CIL #213 - La Mesa
  • CIL #209 - Oceanside
  • CIL #190 - Sacramento
  • CIL #161 - San Diego
  • CIL #113 - San Diego
  • CIL #195 - Santa Ana
  • CIL #119 - Santa Monica
  • CIL #199 - Santa Rosa

Florida

  • CIL #103 - Boca Raton
  • CIL #208 - Hialeah
  • CIL #212 - Homestead

Alabama

  • CIL #138 - Birmingham
  • CIL #218 - Mobile

Arizona

  • CIL #189 - Phoenix

Trial Details

FieldValue
Enrollment Target 601 participants
Start Date 2016-05-12
Est. Completion 2017-04-27
Phase Phase 3
Novan

18 total trials

What the finished NCT02798120 record still lists

NCT02798120 is an interventional study that assigns participants to a tested intervention. The registered 601 participants enrollment target is mid-sized for trials with a published cap, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (126% higher).

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which SB204 4% is the first listed.

NCT02798120 names 20 study sites across 4 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT02798120 about?

NCT02798120 is a clinical study titled "P3 Long Term Safety Study of Once Daily SB204 in Acne". This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.

What is the current status of trial NCT02798120?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 601 participants. The study started on 2016-05-12. Estimated completion is 2017-04-27.

What conditions does trial NCT02798120 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT02798120?

The interventions under investigation include: SB204 4% (DRUG).

Who is sponsoring clinical trial NCT02798120?

This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02798120 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02798120's enrollment target sits among peer trials

601 13th of 67 higher than 55 of 67 other Acne Vulgaris trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acne Vulgaris trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02798120, the US trial registry maintained by the National Library of Medicine. NCT02798120 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.